0001127602-18-033263.txt : 20181115 0001127602-18-033263.hdr.sgml : 20181115 20181115204003 ACCESSION NUMBER: 0001127602-18-033263 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181114 FILED AS OF DATE: 20181115 DATE AS OF CHANGE: 20181115 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Axon Steven CENTRAL INDEX KEY: 0001720605 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 181188491 MAIL ADDRESS: STREET 1: C/O APELLIS PHARMACEUTICALS, INC. STREET 2: 6400 WESTWIND WAY, SUITE A CITY: CRESTWOOD STATE: KY ZIP: 40014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6400 WESTWIND WAY STREET 2: SUITE A CITY: CRESTWOOD STATE: KY ZIP: 40014 BUSINESS PHONE: 502-241-4114 MAIL ADDRESS: STREET 1: 6400 WESTWIND WAY STREET 2: SUITE A CITY: CRESTWOOD STATE: KY ZIP: 40014 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2018-11-14 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001720605 Axon Steven C/O APELLIS PHARMACEUTICALS, INC 6400 WESTWIND WAY, SUITE A CRESTWOOD KY 40014 1 Chief Business Officer Common Stock 2018-11-14 4 M 0 11500 2.59 A 50110 D Stock Option (Right to Buy) 2.59 2018-11-14 4 M 0 11500 0 D 2027-05-17 Common Stock 11500 348389 D This option was granted on May 18, 2017 and has vested as to 25% of the shares underlying the options on January 1, 2018, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through January 1, 2021, subject to continued service. This option was granted on May 18, 2017 and will vest as to 25% of the shares underlying the options on January 1, 2018, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through January 1, 2021, subject to continued service. /s/ David Watson, attorney-in-fact for Steven Axon 2018-11-15